SCHEMBL1122082

SCHEMBL1122082

CN(C)CCn1ccc2ccc(N(S)C(N)=O)cc21

nearest known ligand 0.55

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.55
HTR2C P28335 3/20 0.55
HTR1D P28221 9/20 0.50
NOS3 P29474 6/20 0.47
NOS1 P29475 6/20 0.47
NOS2 P35228 2/20 0.47
HTR6 P50406 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30443765 0.75 HTR2C (0.58) HTR2AHTR2CHTR1DNOS3NOS1
SCHEMBL28814891 0.74 HTR2A (0.51) HTR2AHTR2CHTR1DNOS3NOS1
SCHEMBL1122347 0.74 HTR2C (0.64) HTR2AHTR2CHTR1DNOS3NOS1
Oxalic Acid SCHEMBL23927874 0.73 HTR2A (0.85) HTR2AHTR2CHTR1DHTR6
SCHEMBL27400363 0.72 HTR2C (0.61) HTR2AHTR2CHTR1DNOS3NOS1
SCHEMBL23927832 0.72 HTR2A (1.00) HTR2AHTR2CHTR1DHTR6
SCHEMBL23956080 0.71 HTR2C (0.69) HTR2AHTR2CHTR1DNOS3NOS1
SCHEMBL7252922 0.71 HTR2A (0.64) HTR2AHTR2CHTR1DNOS3NOS1
SCHEMBL31258100 0.71 HTR2A (0.64) HTR2AHTR2CHTR1DNOS3NOS1
SCHEMBL1122080 0.71 HTR2A (0.53) HTR2AHTR2CHTR1DNOS3NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140051687-A1 SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NEURAXON, INC. (CA) 2014-02-20 US disclosed
US-8586620-B2 Substituted indole compounds having NOS inhibitory activity NEURAXON, INC. (CA) 2013-11-19 US disclosed
US-20110212947-A1 SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NEURAXON INC. (CA) 2011-09-01 US disclosed
US-7951940-B2 neuronal nitric oxide synthase (nNOS) isoform inhibitors; 2-ethyl-1-(1H-indol-5-yl)-isothiourea; neurogenerative disorders, stroke, reperfusion injury, head trauma, migraine headache, neuropathic pain, drug abuse, hyperalgesia NEURAXON, INC. (CA) 2011-05-31 US disclosed
EP-1883451-B9 SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NEURAXON INC (CA) 2011-02-09 EP disclosed
EP-1883451-B1 SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NEURAXON INC (CA) 2010-11-24 EP disclosed
US-20080249302-A1 SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NEURAXON INC. (CA) 2008-10-09 US disclosed
US-7375219-B2 Substituted indole compounds having NOS inhibitory activity NEURAXON, INC. (CA) 2008-05-20 US disclosed
US-20060258721-A1 Substituted indole compounds having NOS inhibitory activity NEURAXON INC. (CA) 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212947-A1 SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NOS2, NOS1, NOS3 HTR2A 156/4885HTR2C 434/4885HTR1D 511/4885
US-20080249302-A1 SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NOS2, NOS1, NOS3 HTR2A 156/4885HTR2C 434/4885HTR1D 511/4885
US-20060258721-A1 Substituted indole compounds having NOS inhibitory activity NOS2, NOS1, NOS3 HTR2A 156/4885HTR2C 434/4885HTR1D 511/4885
US-20140051687-A1 SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NOS2, NOS1, NOS3 HTR2A 156/4885HTR2C 434/4885HTR1D 511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.